Introduction
There is growing evidence that psoriasis constitutes a substantial physical burden und may impact the patient's life in various ways [1, 2] . Studies have shown that psoriasis affects both individuals and society, and is often associated with social stigmatization, discomfort, physical disability and emotional distress [3, 4] . Moderate to severe psoriasis accounts for more than 25% of all cases seen in dermatological care [5] , and affected patients experience a similar or even greater reduction in health-related quality of life compared to patients with other chronic diseases [6] . Surveys in a number of countries have revealed a substantial undertreatment of patients with moderate to severe psoriasis, leaving a considerable proportion without adequate disease control. In addition, a high number of patients was not satisfied with their treatment, including the time they needed for skin therapy and the number of visits to physicians [7] . Taking this into account, there has been a substantial effort in describing health care provision and creating a health care environment in which needs and preferences of patients are both taken into consideration when therapeutic interventions are being planned [7] [8] [9] [10] [11] . A recent multinational large-scale survey on psoriasis and psoriatic arthritis (PsA) explored attitudes towards current therapies and identified unmet needs related to the assessment of disease severity, PsA screening and diagnosis and treatment options. Approximately 60% of dermatologists felt that psoriasis patients require more time and support than their other patients and that the current structure of the health care system does not allow them adequate time for their care [12, 13] .
Widespread dissatisfaction with current treatment options was reflected in patients not seeing a physician or not initiating or continuing therapies because of concerns with long-term safety, administration challenges and cost. Although surveys indicate that patients may frequently remain under ineffective treatment for longer than necessary [7, [14] [15] [16] , only few studies have analysed patient satisfaction with health care provision in psoriasis [17] [18] [19] [20] . In the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) study, van de Kerkhof et al. [12] showed that approximately 40% of dermatologists were comfortable, but conservative, in their use of biologic therapy. The main reason for not initiating biologics was related to cost and long-term safety and tolerability concerns.
Reasons that may explain the insufficient health care, especially in patients with moderate to severe psoriasis, are heterogeneous and have not been finally elucidated.
Multiple studies on prescription behaviour have shown that systemic treatments are often not prescribed in accordance with current guidelines, resulting in an undertreatment of patients with moderate to severe disease [21, 22] . Evidence supports the potential value of matching patient preferences to treatment recommendations [23] as they have been shown to affect the patients' treatment satisfaction [24] . Currently, there is no specific instrument available which directly supports clinical decisionmaking and treatment optimization in psoriasis patients based on an easy-to-use questionnaire.
The aim of the present study was to design and validate a questionnaire for patients with psoriasis on satisfaction with psoriasis care, for use in clinical routine and decision-making.
Patients and Methods
For further details, see the supplementary materials (for all online suppl. material, see www.karger.com/doi/10.1159/000444635) [25] [26] [27] ( fig. 1, 2 ) . 
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Results
Development of the PsoSat Questionnaire
The concept of patient satisfaction as part of the clinical decision-making for optimizing psoriasis therapy was based on a theoretical decision algorithm ( fig. 2 ) .
Discussion of items gained from open item survey and consecutive Delphi consensus resulted in a final 8-item solution:
item 1: the current treatment meets my expectations; item 2: I am satisfied with the current treatment; item 3: I wish to have a more effective treatment; item 4: therapy has not been modified according to outcome; item 5: the side effects of the treatment bother me quite a lot; item 6: the current therapy has been conducted for too long without success; item 7: the therapy itself is quite a burden to me; item 8: during the treatment I have to rely on assistance. 
Patient Characteristics in the Validation Study
In total, 213 centres throughout Germany reported n = 2,084 cases, with each dermatologist recruiting on average 9 patients (mean 8.84, SD 1.22, range 4-10). Of these, 201 patients were excluded from analysis because of violation of inclusion/exclusion criteria or too many missing items in the PsoSat Questionnaire, hence n = 1,883 patients were included ( 
Disease Characteristics
The global severity of psoriasis as measured by a 0-10 visual analogue scale score showed a large distribution ( fig. 3 ) with an average score of 5.6 + 2.4.
35.2% (n = 662) of the patients showed nail involvement with an average of 5 fingers involved (mean 5.55, SD 3.22, range 1-10), 44 .7% (n = 841) reported joint pain and 28% (n = 527) suffered from intermittent joint swelling. 959 patients (50.9%) reported comorbidities, mostly vascular disorders (15.2%) and metabolism and nutrition disorders (12.4%).
Impact of Psoriasis on Health-Related Quality of Life
In total 856 patients (45.5%, 'a lot' to 'a little better') reported an improvement of psoriatic symptoms in the previous 4 weeks before the survey. In assessing the state of health with respect to the skin by means of a visual analogue scale (0 = very poor to 10 = excellent), the patients reported an average value of 5.6 (mean 5.64, SD 2.49, range 0-10). The mean Dermatology Life Quality Index score was 6.5 (mean 6.52, SD 5.76, range 0-30; table 2 ).
Psoriasis Therapy
The majority of patients (88.7%) received a topical treatment; only 15% were treated systemically ( table 3 ) .
Treatment Satisfaction (PsoSat)
A majority of patients (n = 1,559; 82.8%) was moderately to very satisfied with therapy ( table 4 ). 19.1% of the patients stated that their treatment expectations were met somehow, and 23% patients were completely satisfied with their current treatment. 39.2% of patients wished to have more effective treatments (significant to high agreement), and 65.7% of the patients stated that therapy was making no progress (quite to high agreement). 108 patients (5.8%) felt to be bothered by treatment side effects (significant to high agreement), and 32.1% of the surveyed patients ascertained that the current therapy had been conducted for too long without success (substantial agreement to perfect agreement). 22.6% of the patients considered therapy itself as a burden (quite to high agreement), and 356 patients (18.9%) had to rely on assistance.
PsoSat Questionnaire -Validation
Item Correlation All individual items correlated significantly with each other. It should be noted that items 3-8 were reversed so that a higher value can be interpreted as higher satisfaction in each area. The correlation coefficients range between r = 0.11 and r = 0.89, with the majority of 17 distinct combinations showing non-negligible coefficients (r >0.3). All individual items correlated significantly with treatment satisfaction and health-related quality of life.
Factor Analysis To investigate whether the observed variables (PsoSat scale items) are due to underlying factors (dimensions), a factor analysis was performed. Because of some not normally distributed items and possible intraclass correlations between different study centres, results were verified by additional tests on reliability. Factor analysis suggested by the Kaiser-Mayer-Oklin and Bartlett tests (sample inclination of 0.81) indicated a 2-scale solution. In all varimax rotations, item 8 ('being dependent on others') showed markedly different properties which did not fit any of the scales.
The reliability test for the remaining 7-item scale supported the results of the factor analysis. A value of 0.86 for Cronbach's α was obtained. The items 1-4 and item 6 increased the internal consistency, the exclusion of item 7 had only a slight deterioration of Cronbach's α result.
According to the results of the factor analysis and reliability tests, two subscales were formed: the first contains the items 1-4 and 6; they reached the highest correlation coefficient with the directly inquired treatment satisfaction (r = 0.66, shared variance 43.7%); the second subscale, with items 5 and 7, correlates with treatment satisfaction only with r = 0.30 (shared variance 9.2%). By contrast, the values of the second subscale can be interpreted as therapy-related stress. The sum of the items 5 and 7 (side effects and treatment burden) correlate well with the active treatment within the past 7 days and show a significant correlation with the number of psoriasis-induced disability days within the last 12 months.
There was a significant but moderate correlation of the overall satisfaction score with quality of life, clinical severity and clinical course of disease in the past 4 weeks. Regarding the single scales, the scale 'satisfaction' correlated highly with the single satisfaction items. By contrast, the second scale, 'burden due to treatment', correlated only mildly with the clinical items, suggesting a different type of construct.
In summary, the final score solution included two scales with 3 and 4 items, respectively. Moreover, a global score was shown to be useful. 
Discussion
The aim of this study was the development, validation and clinical use of a new questionnaire identifying patients in need of treatment changes in psoriasis care. The concept was based on previous publications indicating that in many patients there is need for earlier intervention and/or changes of treatment. For instance, this has been postulated in the European consensus on treatment goals for psoriasis [28] . Moreover, the need for earlier action according to guidelines has been emphasized by the health services studies on quality of care in psoriasis in Germany. The concept developed by psoriasis experts, health research specialists, clinical psychologists and psoriasis patients considers that the need for treatment changes is to be based on several components: (1) an objective failure of treatment, (2) a subjective patient impression of failure, (3) a deterioration of health-related quality of life, (4) patient motivation for change and (5) clinical assessment by the physician. Accordingly, the items developed refer to these 5 areas of interest.
The resulting questionnaire was tested in a large crosssectional study on patients in routine care for psoriasis in Germany. Thus, the data can be considered representative for daily practice in psoriasis. The PsoSat Questionnaire was shown to be a reliable and valid instrument for measuring therapy-related satisfaction and therapy-related stress. The high correlation between the scale used for therapy-related satisfaction and the validation criterion (direct question on therapy-related satisfaction) with high internal consistency of the scale suggests that the construct of therapy-related satisfaction is much more complex than initially assumed and that systematic variance of the scale does not covary with interindividual differences in the validation criterion.
The proportion of patients receiving systemic treatment was low (15%). In a survey conducted by Horn et al. [15] in 1,657 patients with moderate to severe psoriasis, 40% of respondents reported no current treatment at the time of their disease, and less than 50% with severe psoriasis were receiving systemic therapy with a biologic or phototherapy as recommended by the guidelines. In a study published by Armstrong et al. [29] , a total of 5,604 patients with psoriasis or PsA were surveyed. 36.6-49.2% of patients with mild psoriasis were untreated, as well as 23.6-35.5% of patients with moderate psoriasis and 9.4-29.7% of patients with severe psoriasis. These study findings showed that a large proportion of patients with psoriasis did not receive any treatment at all. With the availability of multiple immunomodulatory agents, ensuring that patients are offered these therapeutic options seems to be paramount to improving patient outcomes.
Nearly 25% of the patients assessed in our study were completely satisfied with their current treatment, while 40% wished to have more effective treatments and more than 60% stated that therapy was not making progress. We found the overall percentages of patients being dissatisfied comparable to those reported in previous studies (25-42%) [5, 27, 30] . While numerous treatments for moderate to severe psoriasis have been demonstrated to improve clinical disease and health-related quality of life, older studies have suggested that up to 25-38% of psoriasis patients were dissatisfied with their current treatments [5, 31] . A survey of National Psoriasis Foundation members also found a high rate of dissatisfaction with treatment among psoriasis patients (52.3%) and PsA patients (45.5%), and cited adverse effects and efficacy as the main reasons for discontinuation of biologic therapy. Patientreported outcomes, such as health-related quality of life measures, have been increasingly studied in large randomized trials of psoriasis therapies since conventional clinical measures do not fully inform the effects of disease and treatment on patients [32, 33] . Commonly used health-related quality of life measures focus on the impact of the disease on physical, psychological, and social functioning, but not the impact of the treatment experience on these factors. Treatment satisfaction is a distinct patient-reported outcome, defined as the patient's evaluation of the process of receiving treatment and its associated outcomes [34, 35] . A physician's treatment goals based on the Psoriasis Area and Severity Index may not correlate well with measures of patient satisfaction. The recently published MAPP survey suggested that psoriasis patients and dermatologists may assess disease severity differently and the majority of psoriasis and PsA patients were somewhat satisfied or very satisfied with the effectiveness of conventional oral therapy or biologic therapy, with more PsA patients than psoriasis patients reporting satisfaction. Overall, 31.3% of psoriasis patients reported that their primary goals of therapy, including keeping symptoms at bay, reducing itching and decreasing flaking, were not met with their current treatment [13] .
Treatment satisfaction has been shown to predict adherence, which may affect treatment effectiveness in realworld clinical practice [36] [37] [38] . It is an emerging area of research critical for optimizing effective, patient-centred care and integrating patients' perspectives into clinical practice guidelines [24, 39, 40] .
Patient-centred care fulfils the obligation of health care providers to place the interest of patients first and is associated with improved patient satisfaction, quality of life and better treatment adherence [41, 42] . Recent analysis from clinical trials demonstrates the benefit of treatment goals across various fields of medicine, including psoriasis [43] . A mismatch between physicians' and patients' treatment preferences has been reported on several occasions and may result in patients receiving treatment they are dissatisfied with, which may also affect adherence to treatment and finally patient outcomes [44] . As efficacious treatments are introduced to this patient population, concurrent efforts in advocacy and education are needed to ensure that these medications are accessible to those most likely to benefit and that patients are properly informed of the benefit-risk profiles [29] . It has to be realized that patient satisfaction is contingent upon an immense number of social factors that are not exclusive but rather coexisting determinants of health. Personality may play a role in the interaction of these disease processes with function and health perception. It may also affect the response and interpretation of psychometric and patient-reported outcome measures.
Limitations in the comparability of our data with recent published data arise from the fact that studies were performed in other countries, within the general population. In addition, differences in dissatisfaction percentages could be explained by the availability of better treatments and differences in reimbursement policies. Furthermore, our study is strictly observational. It remains unclear in how many patients and to what extent the results of the proposed tool may have influenced clinical decision-making, as the protocol does not contain information on whether or not treatment has been changed in the patients included. This should be subject to further research and the respective implementation study.
In conclusion, the methodology developed in this project could support the dermatologist and the patient in common decision-making by focusing in a simple way on key variables to be considered in treatment management. Further studies could analyse the long-term impact on such a tool on the quality of health care for psoriasis and on treatment decision-making.
